Boehringer Ingelheim
For Healthcare Professionals
jardiance
Prof-merlin-keyfact1
reduced risk of CV death
or kidney disease progression*1,2
Prof-merlin-keyfact2
reduced risk of CV death
or hospitalisation for heart failure†3,4
Prof-merlin-keyfact3
reduced risk of CV death‡5

How does this early intervention impact the heart?

01/04/2024 | Author: Boehringer Ingelheim

Document ID: PC-SG-102386

Prof Christoph Wanner’s take on EMPA-KIDNEY

What is a typical patient that may benefit from the EMPA-KIDNEY trial results?
How relevant is the broad patient population within EMPA-KIDNEY for a general practitioner's daily practice?
How do you interpret the importance of EMPA-KIDNEY results with regards to the treatment of patients with CKD?
How does this early intervention impact the heart?
How important is early diagnosis and intervention when it comes to CKD?
How do you interpret the results of the primary outcome of EMPA-KIDNEY?
What is the most impactful outcome that was shown in the EMPA-KIDNEY trial?
How do the EMPA-KIDNEY results add up to the existing strong scientific evidence of empagliflozin?
How do the outcomes of the EMPA-KIDNEY trial help patients suffering from kidney disease?
What are the major challenges today with treating kidney disease?

RELATED CONTENT